A METHOD FOR THE DIAGNOSIS AND TREATMENT OF COLORECTAL CANCER

Summary of the technology

A METHOD FOR THE DIAGNOSIS AND TREATMENT OF COLORECTAL CANCER
Project ID : 6-2019-9743

Details of the Technology Offer

Category

LifeSciences and BioTechnology

Keywords

colorectal cancer, gut microbiota, personalized medicine

Current development stage

For Pharmaceutical development: TRL4 - POC & Safety of candidate drug formulation is demonstrated in defined animal model

Application

Identifying, preventing, and treating patients at high risk for developing colorectal cancer.

Our Innovation

The present invention is based on the surprising finding that gut microbiota, and in particular polyphenol producing microbiota, promotes colorectal cancer, and has a clear pro-tumorigenic effect on patients with a specific genetic background.

Our innovation suggests a method to prevent and treat cancer by exposing the patient to gradually reduced amounts of the discovered specific polyphenol.

Technology

Personalized monitoring of microbiota and the associated metabolites content for colorectal cancer patients or people bearing high risk for the disease. The technology will also be used to prevent the development of colorectal cancer in high risk patients as well as treat patients already afflicted by colorectal cancer through dietary measures, antibiotic treatment, or administration of small molecules that reduce the amount of the specific polyphenol .

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Yinon Ben-Neriah
HUJI, School of Medicine - IMRIC
Immunology and Cancer Research

Related Keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • diagnostics
  • Life Science & Biotechnology

About Yissum - Research Development Company of the Hebrew University

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Yissum - Research Development Company of the Hebrew University

Never miss an update from Yissum - Research Development Company of the Hebrew University

Create your free account to connect with Yissum - Research Development Company of the Hebrew University and thousands of other innovative organizations and professionals worldwide

Yissum - Research Development Company of the Hebrew University

Send a request for information
to Yissum - Research Development Company of the Hebrew University

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support